VMAT exposed less circulating blood than IMRT in glioma simulations
VMAT exposed less circulating blood than IMRT, but modeled immune-cell depletion differed by only one percentage point after 30 fractions.
Latest research
Search the archiveMulticenter phantom testing detected and corrected adaptive proton therapy dose errors
A six-center end-to-end framework detected anatomy-induced proton dose deterioration and verified near-complete recovery after adaptive replanning.
CBCT-guided online adaptation consistently improved dosimetry, but clinical evidence remains limited
Across 127 studies, CBCT-guided online adaptation repeatedly improved target coverage and OAR sparing, while evidence for better clinical outcomes remained sparse.
Dynamic IMRT shortened left-breast DIBH delivery while limiting low-dose exposure
Dynamic tangential IMRT delivered left-breast DIBH 42% faster than VMAT with similar target coverage and lower low-dose normal-tissue exposure.
AI supported an MRI-only prostate planning workflow with near-identical dose calculation
AI-generated synthetic CT achieved 99.8% gamma agreement with conventional CT while automated pelvic contours remained within expert interobserver variability.
Partial breast irradiation after sentinel node omission remains an evidence gap
No prospective trial has established the safety of combining partial breast irradiation with sentinel lymph node biopsy omission in early breast cancer.
Spatially fractionated radiotherapy relieved symptoms in most patients with bulky tumors
Spatially fractionated radiotherapy relieved symptoms in 91.7% of patients with bulky advanced tumors without reported grade ≥3 toxicity.
Neoadjuvant chemoradiotherapy was associated with better survival in locally advanced gastric cancer
Neoadjuvant chemoradiotherapy achieved 26.5% pathological complete response and 80.4% five-year survival, outperforming chemotherapy-based strategies in this retrospective cohort.
Proton spot boosting improved prompt-gamma monitoring while largely preserving plan quality
Boosting selected proton spots reduced simulated prompt-gamma noise by up to 93.3% while maintaining acceptable target and organ-at-risk dosimetry.
Long-course chemoradiotherapy improved early organ preservation in STAR-TREC
Twelve-month TME-free survival was 78.5% with long-course chemoradiotherapy versus 60.6% with short-course radiotherapy in early rectal cancer.
Whole-pelvic radiotherapy did not improve survival in high-risk node-negative prostate cancer
Across five phase III trials, whole-pelvic radiotherapy did not improve overall survival, and progression benefits disappeared when POP-RT was excluded.
Postoperative proton therapy achieved 84% five-year local control in paediatric ependymoma
Postoperative proton therapy achieved 84% five-year local control in paediatric ependymoma
Hybrid FLASH preserved normal-tissue sparing when the ultra-high-rate dose remained high
Hybrid ultra-high and conventional dose-rate irradiation retained FLASH sparing in mice, but protection diminished as the ultra-high-rate dose contribution decreased.
Hemithoracic radiotherapy after surgery achieved durable control in pleural thymoma
After surgery and 14 Gy hemithoracic radiotherapy, five-year progression-free survival was 50.8% with only one grade 3 pneumonitis.
Low-dose radiotherapy showed very low in-field solid cancer incidence after musculoskeletal treatment
Only three in-field solid malignancies occurred among 4,699 patients, while marrow-adjacent irradiation was associated with slightly more hematologic malignancies.